Skip to main navigation
  • US
    • 中文

Home

  • BeiGene

Main navigation

  • About
    • Our Story
    • Leadership Team
      • Meet More of Our Team
    • Focus on Quality
    • Who We Are
    • Ethics
  • Science & Pipeline
    • Research & Development
    • Manufacturing
    • Pipeline
      • Zanubrutinib
      • Tislelizumab
      • Pamiparib
      • Lifirafenib
      • Preclinical Candidates
  • Products
  • BeiGene
  • Partnering
    • Partnering with BeiGene
    • Doing Business in China
  • Patients
    • Clinical Trials
    • Access to Investigational Medicines
  • Careers
    • Culture & Benefits
    • Job Opportunities
  • Investors
    • NASDAQ investors
    • HKEX investors
  • Media
  • Contact

Partnerships

Nasdaq Investors
IR Menu
  • Overview
  • Stock
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials
    • SEC Filings
    • Annual Reports
    • Tax Information
    • Shareholder Meeting
  • News & Events
    • Press Releases
    • Events & Calendar
    • Investor Presentation
    • Investor Video
  • Governance
    • Documents & Charters
    • Committee Composition
    • ESG Report
  • IR Resources
    • Investor Services
    • FAQs
    • IR Contact
    • Email Alerts
  • En
  • 中文
  • News & Events
  • Events & Calendar
  • Press Releases
  • Investor Presentation

Events & Calendar

Events & Calendar

Upcoming Events
More events are coming soon.
Past Events
BeiGene, Ltd. at Morgan Stanley 15th Annual Global Healthcare Conference
Sep 12, 2017 at 3:30 PM EDT
Click here for webcast
BeiGene, Ltd. at Baird’s 2017 Global Healthcare Conference
Sep 6, 2017 at 12:15 PM EDT
Click here for webcast
Investor Call to Discuss Global Strategic Collaboration with Celgene
Jul 6, 2017 at 9:00 AM EDT
Click here for webcast
Analyst Call to Discuss BGB-3111 Updates at 14-ICML
Jun 16, 2017 at 8:00 AM EDT
Click here for webcast
ICML Updates on BTK Inhibitor BGB-3111 and its Clinical Development Plan 2.7 MB

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

Find Out More

  • Email alerts

    Sign up to receive e-mail alerts

  • Leadership Team

    Our cooperative and non-heirarchical culture will continue to be instrumental to our success.

  • Investor Contact

    For IR related inquiries.

  • RSS Feeds

  • Email Alerts

  • Print Page

Site Navigation

  • About
  • Science & Pipeline
  • Products
  • BeiGene
  • Partnering
  • Patients
  • Careers

© 2021 BeiGene LTD. All Rights Reserved.

Footer

  • Investors
  • Media
  • Contact
  • Site Map
  • Terms of Use
  • Privacy Policy
❌

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed six drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of February 27, 2019, the Company had a global team of over 2,200 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

❌

Widget - Stock Chart